Tencent Miying Launches AI-supported Auxiliary Diagnostic System
Tencent Miying Launches AI-supported Auxiliary Diagnostic System

Tencent today announces the launch of an AI-supported auxiliary diagnostic system for conducting digital colposcopy at the Global Digital Ecosystem Summit being held in Kunming, China.

Carpe Takes Aim At Groin Sweat, Launches Groin Powder With Precision Lever Sprayer
Carpe Takes Aim At Groin Sweat, Launches Groin Powder With Precision Lever Sprayer

Antiperspirant manufacturer Carpe announced the launch of a new product today: an absorbent powder designed to reduce groin sweat and friction. The powder comes in a compact 10 gram container with a patented precision...

China SXT Pharmaceuticals, Inc. Being Admitted to Hi-tech Zone of Huangshan City in Anhui Province
China SXT Pharmaceuticals, Inc. Being Admitted to Hi-tech Zone of Huangshan City in Anhui Province

China SXT Pharmaceuticals, Inc. (SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces...

NucleusHealth™ Celebrates Year of Milestone Achievements
NucleusHealth™ Celebrates Year of Milestone Achievements

NucleusHealth, the award-winning teleradiology provider and cloud-based medical image management company, today announced the corporate milestones for 2018. The company experienced continued double-digit growth in all...

Akrevia Therapeutics Appoints Rene´ Russo, PharmD, as Chief Executive Officer
Akrevia Therapeutics Appoints Rene´ Russo, PharmD, as Chief Executive Officer

Akrevia Therapeutics, a privately-held biopharmaceutical company focused on developing highly-potent, tumor-targeted immuno-oncology therapeutics, today announced that Rene´ Russo, PharmD, has been appointed as Chief...

Prometic presents new PBI-4050 and Ryplazim™ (plasminogen) data on lung fibrosis at the 2019 ATS Conference
Prometic presents new PBI-4050 and Ryplazim™ (plasminogen) data on lung fibrosis at the 2019 ATS Conference

LAVAL, QC and CAMBRIDGE, United Kingdom, May 22, 2019 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced the presentation of three scientific posters on the Company's lead...

U.S. FDA Grants Priority Review of INVOKANA® (canagliflozin) sNDA for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes
U.S. FDA Grants Priority Review of INVOKANA® (canagliflozin) sNDA for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the supplemental New Drug Application (sNDA) for INVOKANA®...

MAP Health Management Closes Investment From Triton Pacific Capital Partners, LLC.
MAP Health Management Closes Investment From Triton Pacific Capital Partners, LLC.

MAP Health Management ("MAP"), the nation's leading provider of peer recovery support services and data insights for people with Substance Use Disorders, today announced the closing of an investment by Triton Pacific...

Crown Laboratories Acquires Xycrobe™ Therapeutics, Inc., an Innovator in Skin Microbiome Technology
Crown Laboratories Acquires Xycrobe™ Therapeutics, Inc., an Innovator in Skin Microbiome Technology

Crown Laboratories, Inc. ("Crown"), a leading, fully integrated skin care company, today announced it has acquired Xycrobe Therapeutics, Inc. ("Xycrobe").

BioPharmX Announces Last Patient Visit in Phase 2b Trial of BPX-04 for Papulopustular Rosacea
BioPharmX Announces Last Patient Visit in Phase 2b Trial of BPX-04 for Papulopustular Rosacea

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, announced today that the last patient in the Company's Phase 2b clinical...

Alkermes to Present New Data From Mental Health Portfolio at the American Society of Clinical Psychopharmacology 2019 Annual Meeting
Alkermes to Present New Data From Mental Health Portfolio at the American Society of Clinical Psychopharmacology 2019 Annual Meeting

Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from its mental health portfolio at the American Society of Clinical Psychopharmacology (ASCP) 2019 Annual Meeting in Scottsdale, Ariz., May 28-31,...

Scientists Identify New Therapeutic Target for Fatty Liver Disease
Scientists Identify New Therapeutic Target for Fatty Liver Disease

Enleofen Bio ("Enleofen") today announced the publication of promising data from a preclinical study of a novel therapy targeting a severe form of fatty liver disease. The data was published in Gastroenterology, the...

Lilly's Lower-Priced Insulin Now Available
Lilly's Lower-Priced Insulin Now Available

Eli Lilly and Company's (NYSE: LLY) Insulin Lispro Injection is now available for order in pharmacies for people who use Lilly's rapid-acting insulin and need a lower-cost option. Lilly's Insulin Lispro...

Loftware Announces Enterprise Labeling Solution for the Medical Device Industry
Loftware Announces Enterprise Labeling Solution for the Medical Device Industry

Loftware, Inc., the global leader in Enterprise Labeling and Artwork Management Solutions, today announced the availability of Loftware Spectrum for Medical Device. This digital platform is specifically designed to meet...

BioInvent Interim Report January 1 - March 31, 2019
BioInvent Interim Report January 1 - March 31, 2019

Net sales SEK 17.4 (11.3) millionEarnings after tax SEK -27.8 (-24.9) million Earnings after tax per share before and after dilution: SEK -0.08 (-0.08) SEKLiquid funds as of March 31, 2019 SEK 28.5* (108.2) million. Cash...

Amgen announces a recommended public cash offer to the shareholders of Nuevolution
Amgen announces a recommended public cash offer to the shareholders of Nuevolution

The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia, Canada, Hong Kong,...

Nuevolution AB (publ) Announces its Results for the First Quarter of 2019
Nuevolution AB (publ) Announces its Results for the First Quarter of 2019

Nuevolution AB (publ) announces its report for the first quarter of 2019. The report is available on the company's home page (www.nuevolution.com). The following is taken from the quarterly report.

Finding DNA Needles in a Haystack: Worcester Polytechnic Institute Chemical Engineer Helps Develop Biosecurity Tool to Detect Genetically Engineered Organisms in the Wild
Finding DNA Needles in a Haystack: Worcester Polytechnic Institute Chemical Engineer Helps Develop Biosecurity Tool to Detect Genetically Engineered Organisms in the Wild

If a genetically or synthetically engineered organism is released into the environment, how will we know? How can we tell it apart from the millions of microorganisms that exist naturally in the wild? That's the...

Backpack Health Expands Platform Functionality to Integrate Users' Personal Health Records
Backpack Health Expands Platform Functionality to Integrate Users' Personal Health Records

Backpack Health today announced that its health data management platform now has the ability to automatically integrate users' electronic health records, with their consent, into their personal Backpack accounts,...

Noridian Posts Favorable Draft Local Coverage Determination for Natera's Prospera™ Kidney Transplant Test
Noridian Posts Favorable Draft Local Coverage Determination for Natera's Prospera™ Kidney Transplant Test

Noridian, the Medicare Administrative Contractor (MAC) for California-based laboratories, has posted a favorable draft local coverage determination (LCD) for use of Natera's Prospera™ test to assess active rejection in...

Kareo Releases Study Showing the State of Independent Medical Practices and How They Are Managing the Complexities of Care Delivery
Kareo Releases Study Showing the State of Independent Medical Practices and How They Are Managing the Complexities of Care Delivery

Today Kareo released the results of an extensive 2019 study of U.S.-based independent medical practices. Nearly 800 practices participated in the survey that explored opportunities, challenges and priorities in the areas...

OncoSec Granted Exclusive Worldwide Rights To A Patent Portfolio For The Combination Use Of IL-12 DNA With Checkpoint Inhibitors To Treat Cancer In Several Key Countries
OncoSec Granted Exclusive Worldwide Rights To A Patent Portfolio For The Combination Use Of IL-12 DNA With Checkpoint Inhibitors To Treat Cancer In Several Key Countries

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a late-stage biotechnology company developing intratumoral gene-delivery immunotherapies, today announced that the Company has been granted exclusive worldwide rights...

Mesothelioma Victims Center Now Appeals to Construction Workers or Demolition Workers Nationwide with Mesothelioma to Call for Direct Access to Attorney Erik Karst and His Remarkable Colleagues at Karst von Oiste - The Nation's Most Capable Compensation L
Mesothelioma Victims Center Now Appeals to Construction Workers or Demolition Workers Nationwide with Mesothelioma to Call for Direct Access to Attorney Erik Karst and His Remarkable Colleagues at Karst von Oiste - The Nation's Most Capable Compensation L

The Mesothelioma Victims Center says, "Our number one goal for a person with mesothelioma is that they receive the best possible financial compensation. To get the financial compensation job done for any type of...

Veterans Affairs minister meets with Veteran Family Well-Being Fund recipient in Winnipeg
Veterans Affairs minister meets with Veteran Family Well-Being Fund recipient in Winnipeg

The Canadian Virtual Hospice is receiving funding over three year period

New Data Highlights the Value of SPRAVATO™ (esketamine) CIII Nasal Spray, the First New Antidepressant in Decades that Works Differently for Adults with Treatment-Resistant Depression (TRD)[1]
New Data Highlights the Value of SPRAVATO™ (esketamine) CIII Nasal Spray, the First New Antidepressant in Decades that Works Differently for Adults with Treatment-Resistant Depression (TRD)[1]

The Janssen Pharmaceutical Companies of Johnson & Johnson presented a new cost-efficiency analysis at the International Society for Pharmacoeconomics and Outcomes Research Annual Meeting (ISPOR 2019) that illustrates...

Community First Health Plans Expands Relationship with ZeOmega®, Goes Live with LTSS and Nurse Mobility Functionality
Community First Health Plans Expands Relationship with ZeOmega®, Goes Live with LTSS and Nurse Mobility Functionality

ZeOmega, the industry's leading provider of technology-enabled population health management solutions, and Community First Health Plans (CFHP), the only locally-owned, nonprofit health plan in the San Antonio, Texas...

Array BioPharma Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial Interim Analysis for the Treatment of BRAF(V600E)-mutant Metastatic Colorectal Cancer
Array BioPharma Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial Interim Analysis for the Treatment of BRAF(V600E)-mutant Metastatic Colorectal Cancer

Array BioPharma Inc. (Nasdaq: ARRY) today announced positive results from the interim analysis of the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI® (encorafenib), a BRAF inhibitor, MEKTOVI®...

Theravance Biopharma Reports Data from Phase 1b Study of TD-1473 in Oral Presentation at Digestive Disease Week (DDW) 2019
Theravance Biopharma Reports Data from Phase 1b Study of TD-1473 in Oral Presentation at Digestive Disease Week (DDW) 2019

Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today reported data from the exploratory Phase 1b study of the gut-selective pan-Janus kinase (JAK) inhibitor, TD-1473, in an oral...

New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease
New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease

Insmed Incorporated (NASDAQ: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today presented new data from the ongoing Phase 3 CONVERT study of...

Promedior Announces Positive Long-term Safety and Efficacy Data from Open Label Extension Study of PRM-151 in Idiopathic Pulmonary Fibrosis
Promedior Announces Positive Long-term Safety and Efficacy Data from Open Label Extension Study of PRM-151 in Idiopathic Pulmonary Fibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that positive safety and efficacy data from the Company's open-label extension study...

CSA Medical Announces New Data at Digestive Disease Week 2019 Supporting the Safety and Efficacy of truFreeze Spray Cryotherapy for Palliation of Esophageal Cancer
CSA Medical Announces New Data at Digestive Disease Week 2019 Supporting the Safety and Efficacy of truFreeze Spray Cryotherapy for Palliation of Esophageal Cancer

CSA Medical today announced the presentation of two clinical abstracts highlighting the safety and efficacy of truFreeze® Spray Cryotherapy for esophageal cancer (EC) palliation. truFreeze uses the extreme cold of liquid...

Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International Conference
Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International Conference

Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ: MYL) ("Mylan") today announced the presentation of data from its pivotal Phase 3 efficacy studies and a 52-week safety study at the...

EHR Supplier Base in EMEA Remains Highly Fragmented
EHR Supplier Base in EMEA Remains Highly Fragmented

The EMEA market for Electronic Health Record (EHR) IT is estimated to have been worth $3.7B in 2018 (both acute and ambulatory applications) according to Signify Research's 2019 global EMR market report. However, only...

New Post-hoc Analysis Shows Adding UPTRAVI® (selexipag) Versus Placebo Improved Long-Term Clinical Outcomes Regardless of Time of Treatment Initiation, and Demonstrated an Even More Pronounced Treatment Effect When Initiated Early
New Post-hoc Analysis Shows Adding UPTRAVI® (selexipag) Versus Placebo Improved Long-Term Clinical Outcomes Regardless of Time of Treatment Initiation, and Demonstrated an Even More Pronounced Treatment Effect When Initiated Early

Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has presented results of a post-hoc exploratory analysis of the GRIPHON study in patients with pulmonary arterial...

Ava Unveils Unprecedented Insights Into Physical Changes During Menstrual Cycle That Can Be Used to Accurately Identify Fertile Window
Ava Unveils Unprecedented Insights Into Physical Changes During Menstrual Cycle That Can Be Used to Accurately Identify Fertile Window

Ava Science Inc., a women's health care company that focuses on innovative digital technologies, announced today unprecedented insights from a newly published clinical study with its Ava Fertility Tracker. The trial...

Neurocrine Biosciences Presents New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia, Demonstrating the Effect of Involuntary Movements on Patient Quality of Life
Neurocrine Biosciences Presents New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia, Demonstrating the Effect of Involuntary Movements on Patient Quality of Life

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced new data from RE-KINECT, the largest real-world screening study to date of patients with clinician-confirmed possible tardive dyskinesia (TD), demonstrating the...

Stryker receives FDA premarket approval for the Neuroform Atlas® Stent System to treat brain aneurysms
Stryker receives FDA premarket approval for the Neuroform Atlas® Stent System to treat brain aneurysms

Stryker announced today the Premarket Approval (PMA) of the Neuroform Atlas Stent System by the U.S. Food and Drug Administration (FDA).  Neuroform Atlas is only the second aneurysm adjunctive stent to be granted PMA...

UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.
UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.

UCB announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application for the company's newest anti-epileptic drug (AED) NAYZILAM® (midazolam) nasal spray CIV, a benzodiazepine...

Results from Spatz Medical FDA clinical trials confirm that Spatz3, the only Adjustable Gastric Balloon, delivers the highest success rates of all gastric balloons
Results from Spatz Medical FDA clinical trials confirm that Spatz3, the only Adjustable Gastric Balloon, delivers the highest success rates of all gastric balloons

Spatz Medical today announced the FDA trial results of its innovative adjustable gastric balloon. The results demonstrate that the Spatz3 balloon is significantly more effective than any non-adjustable balloon in the market.

Bridge Biotherapeutics Announces Data Presentation from First-in-Human Study of BBT-877 for Idiopathic Pulmonary Fibrosis
Bridge Biotherapeutics Announces Data Presentation from First-in-Human Study of BBT-877 for Idiopathic Pulmonary Fibrosis

Bridge Biotherapeutics Inc., a clinical-stage biotech company developing novel therapeutics for areas with high unmet medical needs, announced that the company presented interim data from a Phase I clinical study on...

ISO 13485:2016 and ISO 9001:2015 Facility Expansion and Operational Efficiency Improvements
ISO 13485:2016 and ISO 9001:2015 Facility Expansion and Operational Efficiency Improvements

High Performance Medical Solutions (HPMS), a division of Hitachi Cable America Inc., has expanded its Rhode Island and Connecticut operations. Since the acquisition of HTP-MEDS (now HPMS) in early 2016, we have instituted...

New Real-World Evidence Highlights Need for Interventions to Improve Outcomes for Patients Who Have Been Diagnosed with Major Depressive Disorder (MDD) and Suicide Ideation or Attempt
New Real-World Evidence Highlights Need for Interventions to Improve Outcomes for Patients Who Have Been Diagnosed with Major Depressive Disorder (MDD) and Suicide Ideation or Attempt

Janssen Pharmaceutical Companies of Johnson & Johnson presented new real-world data at the American Psychiatric Association (APA) 2019 Meeting which suggest that, among adult patients with major depressive disorder...

Weight Loss Surgery for Pakistani Youngster is a Reminder that Bariatric Medicine is Saving Lives Every Day, says Dr. Feiz & Associates
Weight Loss Surgery for Pakistani Youngster is a Reminder that Bariatric Medicine is Saving Lives Every Day, says Dr. Feiz & Associates

A May 3 article on Daily Mail UK reports that a Pakistani boy believed by his doctors to be the heaviest known youngster worldwide will soon be undergoing potentially life-saving bariatric surgery. The child, Mohammed...

NIH administers first clinical trial treatment for GM1 created by Auburn, UMass
NIH administers first clinical trial treatment for GM1 created by Auburn, UMass

The first clinical trial of a gene therapy treatment created through a research alliance between Auburn University and the University of Massachusetts has been administered in a child at the National Institutes of Health,...

Lawrence General Hospital RNs Vote to Ratify New Three-Year Contract
Lawrence General Hospital RNs Vote to Ratify New Three-Year Contract

The nurses of Lawrence General Hospital voted this week to ratify a new three-year contract that nurses believe will allow the hospital to recruit and retain the staff needed to ensure optimum patient care.

Entertainment 

Health 

Technology